Pfizer collaborates for Phase III axitinib Asia trial
This article was originally published in Scrip
Executive Summary
Pfizer has inked a deal with SFJ Pharma Ltd II, a drug development company that specialises in obtaining regulatory approval for drugs for the Japanese market, to conduct a Phase III clinical study for the investigational agent axitinib in six Asian countries.